Page last updated: 2024-12-07

(S)-3-hydroxybutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## (S)-3-Hydroxybutyric Acid: A Fuel Source and Beyond

**(S)-3-hydroxybutyric acid**, often shortened to **(S)-3-HB**, is a ketone body, a naturally occurring compound produced in the liver during periods of fasting or prolonged exercise. It's a significant source of energy for the brain and other tissues, particularly when glucose levels are low.

Here's why (S)-3-HB is important for research:

**1. Energy Metabolism and Alternative Fuel:**

* **Metabolic switch:** During fasting or prolonged exercise, the body shifts from relying on glucose to utilizing ketone bodies, including (S)-3-HB, as an energy source. This metabolic switch is crucial for survival and performance.
* **Brain fuel:** (S)-3-HB is the primary ketone body used by the brain, especially during prolonged fasting or ketosis. This has implications for understanding brain function and neurodegenerative diseases.
* **Therapeutic potential:** (S)-3-HB is being explored as a potential therapeutic agent for various conditions, including:
* **Neurological disorders:** Alzheimer's disease, Parkinson's disease, epilepsy, stroke.
* **Metabolic disorders:** Type 2 diabetes, obesity, non-alcoholic fatty liver disease.
* **Cancer:** Some studies suggest (S)-3-HB may have anticancer effects.

**2. Beyond Energy:**

* **Epigenetic regulation:** (S)-3-HB can act as a signaling molecule, affecting gene expression through epigenetic mechanisms. This opens avenues for studying its role in development, aging, and disease.
* **Anti-inflammatory effects:** (S)-3-HB has been shown to possess anti-inflammatory properties, potentially relevant to chronic inflammatory diseases like arthritis and inflammatory bowel disease.
* **Neuroprotective effects:** (S)-3-HB has demonstrated neuroprotective effects against oxidative stress and apoptosis, suggesting its potential role in preventing neurodegenerative diseases.

**3. Research Applications:**

* **Development of ketone-based therapies:** Developing new therapies based on (S)-3-HB and other ketone bodies to treat various diseases.
* **Understanding metabolic pathways:** Exploring the intricate mechanisms of ketone body production and utilization, shedding light on metabolic regulation.
* **Investigating the role of (S)-3-HB in health and disease:** Examining the impact of (S)-3-HB on various physiological processes, including brain function, immune response, and inflammation.

**In summary,** (S)-3-hydroxybutyric acid is a fascinating molecule with multiple roles in the body, ranging from energy metabolism to gene regulation. Its diverse biological actions and potential therapeutic applications make it an active area of research with exciting possibilities for future medical advancements.

(S)-3-hydroxybutyric acid : The S-enantiomer of 3-hydroxybutyric acid; a normal human metabolite, that has been found elevated in geriatric patients remitting from depression. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID94318
CHEMBL ID1162497
CHEBI ID17290
SCHEMBL ID336331

Synonyms (71)

Synonym
(+)-3-hydroxybutyric acid
l-(+)-3-hydroxybutyric acid
(s)-3hb
(3s)-3-hydroxybutyric acid
l-3-hydroxybutyric acid
6168-83-8
(s)-3-hydroxybutyric acid
(s)-beta-hydroxybutyric acid
(3s)-3-hydroxybutanoic acid
(s)-3-hydroxybutanoic acid
CHEBI:17290 ,
3hl ,
(s)-3-hydroxybutanoate
C03197
MLS001333230
MLS001333229
smr000857204
(s)-3-hydroxybutyric acid, >=97.0%
(s)-3-hydroxy-2-methyl-propanoic acid
3-hydroxy-butyrate ,
CHEMBL1162497 ,
NCGC00247035-01
bdbm50344957
AKOS006239831
HMS2231P22
beta-hydroxybutyrate, l-
unii-vk6om9m3wp
einecs 228-209-4
3-hydroxybutanoic acid, (s)-
vk6om9m3wp ,
beta-hydroxybutyrate,l
.beta.-hydroxybutyric acid d-form [mi]
(s)-.beta.-hydroxybutanoic acid
(s)-(+)-.beta.-hydroxybutyric acid
butanoic acid, 3-hydroxy-, (3s)-
beta-l-hydroxybutyrate
gtpl4699
beta-l-hydroxybutyric acid
SCHEMBL336331
WHBMMWSBFZVSSR-VKHMYHEASA-N
DS-2801
HB4641
LMFA01050463
mfcd00137685
(3s)-3-hydroxy-butanoate
l-(+)-2-methyl-hydracrylic acid
l-(+)-b-hydroxyisobutyrate
(s)-beta-hydroxyisobutyrate
l-(+)-beta-hydroxyisobutyrate
(s)-3-hydroxy-2-methyl-propanoate
(s)-3-hydroxy-butanoic acid
(3s)-3-hydroxy-butanoic acid
l-(+)-2-methyl-hydracrylate
(s)-b-hydroxyisobutyric acid
(s)-b-hydroxyisobutyrate
(+)-3-hydroxy-n-butyric acid
(s)-3-hydroxy-butanoate
l-beta-hydroxybutyrate
l-(+)-b-hydroxyisobutyric acid
HY-W050031
DTXSID80904613
s-3-hydroxybutanoic acid
CS-0031375
Q27075158
AMY24175
l-b-hydroxybutyric acid
(s)-b-hydroxybutanoic acid
A868649
(s)-3-hydroxybutanoicacid
EN300-114854
l-??hydroxybutyric acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
3-hydroxybutyric acidA straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency1.00000.707936.904389.1251AID504333
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
gemininHomo sapiens (human)Potency0.14580.004611.374133.4983AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 20Mus musculus (house mouse)Ki190.54601.10006.67899.1201AID360149
Solute carrier family 22 member 6Mus musculus (house mouse)Ki3,258.64660.40745.02179.4000AID360150; AID598874; AID598880
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
lactate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
pyruvate catabolic processMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transportMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transportMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
RNA bindingMonocarboxylate transporter 4Homo sapiens (human)
protein bindingMonocarboxylate transporter 4Homo sapiens (human)
monocarboxylic acid transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
lactate:proton symporter activityMonocarboxylate transporter 4Homo sapiens (human)
pyruvate transmembrane transporter activityMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
apical plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
lateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
nuclear membraneMonocarboxylate transporter 4Homo sapiens (human)
plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
basolateral plasma membraneMonocarboxylate transporter 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID598874Inhibition of mouse Oat1 expressed in Xenopus oocytes assessed as inhibition 6-carboxyfluorescein uptake after 1 hr by fluorometric analysis2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1).
AID360151Ratio of pKi for mouse Oat1 expressed in Xenopus oocytes to pKi for mouse Oat6 expressed in Xenopus oocytes2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID360149Inhibition of mouse Oat6-mediated [3H]ES uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID360150Inhibition of mouse Oat1-mediated [3H]PAH uptake in Xenopus oocytes after 1 hr2007The Journal of biological chemistry, Aug-17, Volume: 282, Issue:33
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.
AID598880Inhibition of mouse Oat1 expressed in Xenopus oocytes2011Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11
Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1).
AID681140TP_TRANSPORTER: uptake in Xenopus laevis oocytes2000The Journal of physiology, Dec-01, Volume: 529 Pt 2Characterisation of human monocarboxylate transporter 4 substantiates its role in lactic acid efflux from skeletal muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's4 (50.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.88 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]